The company intends to speed-up planned clinical testing of Brilacidin for Covid-19. Credit: Fusion Medical Animation on Unsplash.

Innovation Pharmaceuticals has reported promising data from ongoing in-vitro testing of its Brilacidin at a US Regional Biocontainment Laboratory (RBL) to treat Covid-19.

Data showed that Brilacidin has a high selectivity index (SI), used to compare the antiviral efficacy between investigational drugs.

In a human lung epithelial cell line, the drug’s SI proved greater than 300, higher than the SIs of a majority of other antiviral drugs tested against Covid-19, said the company.

Innovation Pharmaceuticals CEO Leo Ehrlich said: “Selectivity Index is arguably the most important measure to compare the antiviral efficacy between experimental drugs, and this new data suggests Brilacidin is in an elite group of anti-coronavirus candidates.

“Unlike thousands of other compounds and drugs under consideration as Covid-19 treatments, Brilacidin is demonstrating remarkably consistent and potent anti-SARS-CoV-2 activity in RBL testing, suggesting Brilacidin has tremendous potential as a Covid-19 treatment.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

With direct incubation of the live (or wild type) virus, the drug caused inhibition by 50% (IC50 value) at a mid-nanomolar concentration, in a human lung epithelial cell line.

Findings also revealed that the drug was non-cytotoxic to cells at high micromolar concentrations. Brilacidin’s IC90 value was in the low micromolar range.

A recent screening of 5,632 compounds, including 3,488 subjected to clinical-stage testing across 600 indications, only 19 possessed an IC50 in the nanomolar (<1µM) range against Covid-19, demonstrated by Brilacidin.

The company intends to speed-up planned clinical testing of its drug for Covid-19 treatment, including the selection of clinical trial sites. Discussions with the US Food and Drug Administration (FDA) should begin early next month.

Production of intravenous (IV) drug product could generate an amount above the estimated requirement for the planned Phase II trial, allowing extra support for further Covid-19 clinical testing.